Gabelli & CO Investment Advisers, Inc. Incyte Corp Transaction History

Gabelli & CO Investment Advisers, Inc.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2018 Aug 10, 2018	SELL	$60.85 - $83.98 $1.03 Million - $1.42 Million	-16,900 Closed	0 $0
Q1 2018 May 09, 2018	BUY	$83.06 - $100.98 $539,890 - $656,370	6,500 Added 62.5%	16,900 $1.41 Million
Q4 2017 Feb 02, 2018	SELL	$93.56 - $116.6 $355,528 - $443,080	-3,800 Reduced 26.76%	10,400 $985,000
Q3 2017 Nov 01, 2017	BUY	$109.15 - $138.27 $1.55 Million - $1.96 Million	14,200	14,200 $1.66 Million

643

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $15.4B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Gabelli & CO Investment Advisers, Inc., based on Form 13F filings with the SEC.

Stay updated on Gabelli & CO Investment Advisers, Inc. with notifications on news.